- 4-Week # shares bought: 1,250
- 4-Week # shares sold: 5,000
- 12-Week # shares bought: 1,250
- 12-Week # shares sold: 197,135
- 24-Week # shares bought: 2,250
- 24-Week # shares sold: 280,351
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.